fashion -WSS

fashion

author：knowledge 2025-09-28 21:54:17 - browse：1

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. — Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

“It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Medicare drug price negotiation program allowed for now

WSS

After a drawn out lobbying fight, ARPA

Colorectal cancer study finds potential in overlooked immune cell

After a drawn out lobbying fight, ARPA

3 questions for the future of Biden's cancer moonshot

Shingles, which affected Dianne Feinstein, is on the rise

Would Medicare drug price negotiations stall in a shutdown?

leisure time

fashion

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Researchers use wearables data and AI to predict preterm birth risk

In age of alternative facts, a scholarly course on calling out crap

Senate panel eyes new effort on drug shortages

Walensky prepares to leave CDC — and Congress — behind

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Jerome Adams on the need for new antivirals for Covid

Chemotherapy drug shortage eases slightly but still widespread

leisure time

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

FDA advisers vote against ALS treatment from BrainStorm

Listen: Who gets the credit for GLP

What to expect at HLTH 2023, the health care industry conference

The future of health care in the House

Cigna to pay $172 million to settle Medicare Advantage fraud probe

hotspot

entertainment

hotspot

leisure time